Stockreport

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]

Prothena Corporation plc - Ordinary Shares  (PRTA) 
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.prothena.com
PDF Prasinezumab continues to be well tolerated and no new safety signals were observed Roche is further evaluating the data and will work together with health authoritie [Read more]